Early intervention and prevention of lung disease in cystic fibrosis: A European consensus

Journal of Cystic Fibrosis

Volumn 3, Issue 2, 2004, Pages 67-91

  Döring, Gerd ^a   Hoiby, Niels ^a   Assael, Baroukh ^b   Ballmann, Manfred ^c   Bush, Andrew ^d   Button, Brenda ^e   Clement, Annick ^f   Conway, Steven ^g   Dankert Roelse, Jeanette ^h   de Baets, Frans ⁱ   De Boeck, Christiane ^j   de Braekeleer, Marc ^k   Elborn, Stuart ^l   Farell, Philip ^m   Frederiksen, Birgitte ⁿ   Govan, John ^o   Kerem, Eitan ^p   Hodson, Margaret ^d   Holby, Niels ⁿ   Koch, Christian ⁿ   Lannefors, Louise ^q   Lee, Tim ^r   Lindblad, Anders ^s   Littlewood, James ^t   Mehta, Anil ^u   Munck, Anne ^v   Navarro, Jean ^v   Pitt, Tyron ^w   Pressler, Tanja ⁿ   Raia, Valeria ^x   Ratjen, Felix ^y   Romano, Luca ^z   Stern, Martin ^aa   Taccetti, Giovanni ^ab   Vandamme, Peter ⁱ   Wainwright, Claire ^ac   Webb, Kevin ^ad   Worlitzsch, Dieter ^a   more..

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b BORGO TRENTO HOSPITAL   (Italy)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d ROYAL BROMPTON HOSPITAL   (United Kingdom)

^e ALFRED HOSPITAL   (Australia)

^f ARMAND TROUSSEAU HOSPITAL   (France)

^g SEACROFT HOSPITAL   (United Kingdom)

^h VU UNIVERSITY AMSTERDAM   (Netherlands)

ⁱ GHENT UNIVERSITY   (Belgium)

^j UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^k BREST UNIVERSITY HOSPITAL   (France)

^l BELFAST CITY HOSPITAL   (United Kingdom)

^m UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

ⁿ Rigshospitalet   (Denmark)

^o UNIVERSITY OF EDINBURGH   (United Kingdom)

^p SHAARE ZEDEK MEDICAL CENTER   (Israel)

^q LUND UNIVERSITY HOSPITAL   (Sweden)

^r ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^s SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^t Ninewells Hospital/Medical School ^*

^u UNIVERSITY OF DUNDEE   (United Kingdom)

^v HÔPITAL ROBERT DEBRÉ   (France)

^w PUBLIC HEALTH ENGLAND   (United Kingdom)

^x FEDERICO II UNIVERSITY HOSPITAL   (Italy)

^y UNIVERSITY HOSPITAL ESSEN   (Germany)

^z G GASLINI INSTITUTE   (Italy)

^aa UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^ab UNIVERSITY OF FLORENCE   (Italy)

^ac ROYAL CHILDREN'S HOSPITAL   (Australia)

^ad WYTHENSHAWE HOSPITAL   (United Kingdom)

more..

Author keywords

Cystic fibrosis; European consensus; Lung disease

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; AZITHROMYCIN; AZTREONAM; CEFTAZIDIME; CEFUROXIME AXETIL; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CLARITHROMYCIN; CLINDAMYCIN; COLISTIN; COTRIMOXAZOLE; DICLOXACILLIN; DOXYCYCLINE; FLUCLOXACILLIN; FUSIDIC ACID; LINEZOLID; MEROPENEM; MONOBACTAM DERIVATIVE; MOXIFLOXACIN; PENICILLIN DERIVATIVE; PIVAMPICILLIN; RIFAMPICIN; TEICOPLANIN; TIMENTIN; TOBRAMYCIN; UNINDEXED DRUG; VANCOMYCIN;

ANTIBIOTIC THERAPY; BREATHING EXERCISE; CONSENSUS DEVELOPMENT; CROSS INFECTION; CYSTIC FIBROSIS; EARLY DIAGNOSIS; EUROPE; HAEMOPHILUS INFLUENZAE; HEALTH STATUS; HUMAN; INFECTION PREVENTION; NONHUMAN; PATIENT MONITORING; PERSONAL HYGIENE; PSEUDOMONAS AERUGINOSA; RECURRENT INFECTION; REVIEW; STAPHYLOCOCCUS AUREUS;

EID: 3343023861     PISSN: 15691993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcf.2004.03.008     Document Type: Article

References (317)

1. Ratjen F. Döring G. Cystic Fibrosis Lancet 361 2003 681-689
2. Cystic Fibrosis Foundation Patient Registry 2001 Annual Data Report 2002 Cystic Fibrosis Foundation Bethesda (MD), USA
3. Stern M. Sens B. Wiedemann B. Busse O. Qualitätssicherung Mukoviszidose-Überblick über den Gesundheitszustand der Patienten in Deutschland 2001 Zentrum für Qualitätsmanagement im Gesundheitswesen 2002 Ärztekammer Hannover Germany
4. Koch C. McKensey S.G. Kaplowitz H. Hodson M.E. Horms H.K. Navarro J. Mastella G. International practice patterns by age and severity of lung disease in cystic fibrosis: data of the Epidemiologic Registry of Cystic Fibrosis (ERCF) Pediatr. Pulmonol. 24 1997 147-154
5. Döring G. et al. For the Consensus Committee Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus Eur. Respir. J. 16 2000 749-767
6. Antibiotic treatment for Cystic Fibrosis Report of the UK cystic fibrosis trust antibiotic group second edition 2002 Cystic Fibrosis Trust London, UK
7. Murray J. Cuckle H. Taylor G. Littlewood J.M. Hewison J. Screening for cystic fibrosis Health Technol. Assess. 3 1999 1-104
8. Farrell P.M. Fost N. Prenatal screening for cystic fibrosis: where are we now? J. Pediatr. 141 2002 758-763
9. Brock D.J.H. Screening In: Hodson M.E. Geddes D.(Eds.) Cystic fibrosis 2000 189-202 Arnold London
10. Dankert-Roelse J.E. te Meerman G.J. Knol K. ten Kate L.P. Effect of screening for cystic fibrosis on the influence of genetic counseling Clin. Genet. 32 1987 271-275
11. Dudding T. Wilcken B. Burgess B. Turner G. Neonatal screening for cystic fibrosis Lancet 356 2000 1930
12. Merelle M.E. Huisman J. Alderden van der Vecht A. Taat F. Bezemer D. Griffioen R.W. et al. Early versus late diagnosis: psychological impact on parents of children with cystic fibrosis Pediatrics 111 2003 346-350
13. Southern K.W. Littlewood J.M. Neonatal cystic fibrosis screening worldwide Paediatric respiratory reviews 4 2003 299-305
14. Centers for disease control and prevention Newborn screening for cystic fibrosis: a paradigm for public health genetics policy development Morb. Mortal. Wkly. Rep. 46 1997 [RR-16]
15. Scotet V. de Braekeleer M. Roussey M. Rault G. Parent P. Dagorne M. et al. Neonatal screening for cystic fibrosis in Brittany, France: assessment of 10 years' experience and impact on prenatal diagnosis Lancet 356 2000 789-794
16. Bobadilla J.L. Macek M.Jr. Fine J.P. Farrell P.M. Cystic fibrosis: a worldwide analysis of CFTR mutations-correlation with incidence data and application to screening Hum. Mutat. 19 2002 575-606
17. Wang S.S. O'Leary L.A. FitzSimmons S.C. Khoury M.J. The impact of early cystic fibrosis diagnosis on pulmonary function in children J. Pediatr. 141 2002 804-810
18. Farrell P. Kosorok M. Laxova A. Shen G. Koscik R.E. Bruns W.T. et al. Nutritional benefits of neonatal screening for cystic fibrosis N. Engl. J. Med. 337 1997 963-969
19. Farrell P.M. Kosorok M.R. Rock M.J. Laxova A. Zeng L. Lai H.C. et al. Early diagnosis of cystic fibrosis through neonatal screening prevents severe malnutrition and improves long-term growth. Wisconsin Cystic Fibrosis Neonatal Screening Study Group Pediatrics 107 2001 1-13
20. Wilcken B. Chalmers G. Reduced morbidity in patients with cystic fibrosis detected by neonatal screening Lancet ii 1985 1319-1321
21. Chatfield S. Owen G. Ryley H.C. Williams J. Alfaham M. Goodchild M.C. et al. Neonatal screening for cystic fibrosis in Wales and the West Midlands: clinical assessment after five years of screening Arch. Dis. Child. 66 1991 29-33
22. Bowling F. Cleghorn G. Chester A. Curran J. Griffin B. Prado J. et al. Neonatal screening for cystic fibrosis Arch. Dis. Child. 63 1988 196-200
23. Dankert-Roelse J.E. teMeerman G.J. Martijn A. ten Kate L.P. Knol K. Survival and clinical outcome in patients with cystic fibrosis, with or without neonatal screening J. Pediatr. 14 1989 362-367
24. Waters D.L. Wilcken B. Irwing L. Van Asperen P. Mellis C. Simpson J.M. Clinical outcomes of newborn screening for cystic fibrosis Arch. Dis. Child. 80 1999 F1-F7
25. Siret D. Bretaudeau G. Branger B. Dabadie A. Dagorne M. David V. et al. Comparing the clinical evolution of cystic fibrosis screened neonatally to that of cystic fibrosis diagnosed from clinical symptoms: a 10-year retrospective study in a French region (Brittany) Pediatr. Pulmonol. 35 2003 342-349
26. Wang S.S. FitzSimmons S.C. O'Leary L.A. Rock M.J. Gwinn M.L. Khoury M.J. Early diagnosis of cystic fibrosis in the newborn period and risk of Pseudomonas aeruginosa in the first 10 years of life: a registry-based longitudinal study Pediatrics 107 2001 274-279
27. Merelle M.E. Schouten J.P. Gerritsen J. Dankert-Roelse J.E. Influence of neonatal screening and centralized treatment on long-term clinical outcome and survival of CF patients Eur. Respir. J. 18 2001 306-315
28. Mehta G. Green M. Mehta A. Confidential anonymous audit shows that neonatal CF screening saves lives in severe genotype CF. J Cystic Fibrosis 2001. Suppl. Abstracts of the 24th European Cystic Fibrosis Conference 6-9th June, Vienna, Austria. WS2.
29. Doull I.J.M. Ryley H.C. Weller P. Cystic fibrosis-related deaths in infancy and the effect of newborn screening Pediatr. Pulmonol. 31 2001 363-366
30. Assael B.M. Castellani C. Barao Ocampo M. Iansa P. Callegaro A. Valsecchi M.G. Epidemiology and survival analysis of cystic fibrosis in an area of intense neonatal screening over 30 years Am. J. Epidemiol. 156 2002 397-401
31. Dankert-Roelse J.E. te Meerman G.J. Long term prognosis of patients with cystic fibrosis in relation to early detection by neonatal screening and treatment in a cystic fibrosis centre Thorax 50 1995 712-718
32. Mahadeva R. Webb K. Westerbeek R.C. Carroll N.R. Dodd M.E. Bilton D. et al. Clinical outcome in relation to care in centres specialising in cystic fibrosis: cross sectional study BMJ 316 1998 1771-1775
33. Dankert-Roelse J.E. te Meerman G.J. Screening for cystic fibrosis-time to change our position? N. Engl. J. Med. 337 1997 997-999
34. Kahl B. Herrmann M. Everding A.S. Koch H.G. Becker K. Harms E. et al. Persistent infection with small colony variant strains of Staphylococcus aureus in patients with cystic fibrosis J. Infect. Dis. 177 1998 1023-1029
35. Burns J.L. Emerson J. Stapp J.R. Yim D.L. Krzewinski J. Louden L. et al. Microbiology of sputum from patients at cystic fibrosis centers in the United States Clin. Infect. Dis. 27 1998 158-163
36. Konstan M.W. Hilliard K.A. Norvell T.M. Berger M. Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation Am. J. Respir. Crit. Care Med. 150 1994 448-454
37. Rosenfeld M. Gibson R.L. McNamara S. Emerson J. Burns J.L. Castile R. et al. Early pulmonary infection, inflammation, and clinical outcomes in infants with cystic fibrosis Pediatr. Pulmonol. 32 2001 356-366
38. Burns J.L. Gibson R.L. McNamara S. Yim D. Emerson J. Rosenfeld M. et al. Longitudinal assessment of Pseudomonas aeruginosa in young children with cystic fibrosis J. Infect. Dis. 183 2001 444-452
39. Dakin C.J. Numa A.H. Wang H. Morton J.R. Vertzyas C.C. Henry R.L. Inflammation, infection, and pulmonary function in infants and young children with cystic fibrosis Am. J. Respir. Crit. Care Med. 165 2002 904-910
40. Armstrong D.S. Grimwood K. Carlin J.B. Carzino R. Gutierrez J.P. Hull J. et al. Lower airway inflammation in infants and young children with cystic fibrosis Am. J. Respir. Crit. Care Med. 156 1997 1197-1204
41. De Boeck K. Alifier M. Vandeputte S. Sputum induction in young cystic fibrosis patients Eur. Respir. J. 16 2000 91-94
42. Döring G. Høiby N. Longitudinal study of immune response to Pseudomonas aeruginosa antigens in cystic fibrosis Infect. Immun. 42 1983 197-201
43. Brett M.M. Simmonds E.J. Ghoneim A.T.M. Littlewood J.M. The value of serum IgG titres against Pseudomonas aeruginosa in the management of early pseudomonal infection in cystic fibrosis Arch. Dis. Child. 67 1992 1086-1088
44. West S.E. Zeng L. Lee B.L. Kosorok M.R. Laxova A. Rock M.J. et al. Respiratory infections with Pseudomonas aeruginosa in children with cystic fibrosis: early detection by serology and assessment of risk factors JAMA 287 2002 2958-2967
45. Corey M. Canadian Cystic Fibrosis Foundation Patient data registry 1996 Toronto, Canada
46. FitzSimmons S.C. Cystic Fibrosis Patient Registry Annual data report 1997 1998 Bethesda, Maryland
47. Navarro J. Rainisio M. Harms H.K. Hodson M.E. Koch C. Mastella G. et al. Factors associated with poor pulmonary function: cross-sectional analysis of data from the ERCF. European Epidemiologic Registry of Cystic Fibrosis Eur. Respir. J. 18 2001 298-305
48. Dodge J.A. Morison S. Lewis P.A. Coles E.C. Geddes B. Russell G. et al. (The UK Survey Management Committee). Incidence, population and survival of cystic fibrosis in the UK, 1968-95 Arch. Dis. Child. 77 1997 493 496
49. Wiedemann B. Steinkamp G. Sens B. Stern M.for the German Cystic Fibrosis Quality Assurance Group The German cystic fibrosis quality assurance project: clinical features in children and adults Eur. Respir. J. 17 2001 1187-1194
50. De Braekeleer M. Bellis G. Observatoire national de la mucoviscidose (ONM): structure de l'observatoire et résultats de l'enquête 1999 Réf. Mucoviscid. 6 2001 42-48
51. McCormick J. Green M.W. Mehta G. Culross F. Mehta A. Demographics of the UK Cystic Fibrosis Population: implications for the National Screening Programme Eur. J. Hum. Genet. 10 2002 583-590
52. Mehta G. Sims E.J. Culross F. McCormick J.D. Mehta A. Potential advantages of the UKCF Database J. Royal Soc. Medicine 97 Suppl. 44 2004 60-71
53. Liou T.G. Adler F.R. FitzSimmons S.C. Cahill B.C. Hibbs J.R. Marshall B.C. Predictive 5-year survivorship model of cystic fibrosis Am. J. Epidemiol. 153 2001 345-352
54. Di Sant'Agnese P.A. Andersen D.H. Celiac syndrome: chemotherapy in infection of the respiratory tract associated with cystic fibrosis of the pancreas; observation with penicillin and drugs of the sulphonamide groups, with special reference to penicillin aerosol Am. J. Dis. Child. 72 1946 17-61
55. Høiby N. Frederiksen B. Microbiology In: Hodson M.E. Geddes D.(Eds.) Cystic fibrosis 2000 83-108 Arnold London
56. Saiman L. Siegel J. Infection control recommendations for patients with cystic fibrosis: microbiology, important pathogens, and infection control practices to prevent patient-to-patient transmission Infect. Control Hosp. Epidemiol. 24 2003 S6-S52 [Suppl.]
57. Andersen D.H. Cystic fibrosis of the pancreas and its relation to celiac disease Am. J. Dis. Child. 56 1938 344-399
58. Miall L.S. McGinley N.T. Brownlee K.G. Conway S.P. Methicillin resistant Staphylococcus aureus (MRSA) infection in cystic fibrosis Arch. Dis. Child. 84 2001 160-162
59. Thomas S.R. Gyi K.M. Gaya H. Hodson M.E. Methicillin-resistant Staphylococcus aureus: impact at a national cystic fibrosis centre J. Hosp. Infect. 40 1998 203-209
60. Doggett R.G. Harrison G.M. Stillwell R.N. Wallis E.S. An atypical Pseudomonas aeruginosa associated with cystic fibrosis of the pancreas J. Pediatr. 68 1966 215-221
61. Kosorok M.R. Zeng L. West S.E. Rock M.J. Splaingard M.L. Laxova A. et al. Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition Pediatr. Pulmonol. 32 2001 277-287
62. Regelmann W.E. Elliott G.R. Warwick W.J. Clawson C.C. Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than do bronchodilators and chest physiotherapy alone Am. Rev. Respir. Dis. 141 1990 914-921
63. Frederiksen B. Lanng S. Koch C. Høiby N. Improved survival in the Danish center-treated cystic fibrosis patients: results of aggressive treatment Pediatr. Pulmonol. 21 1996 153-158
64. Ramsey B.W. Pepe M.S. Quan J.M. Otto K.L. Montgomery A.B. Williams-Warren J. et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group N. Engl. J. Med. 340 1999 23-30
65. May J.R. Herrick N.C. Thompson D. Bacterial infection in cystic fibrosis Arch. Dis. Child. 47 1972 908-913
66. Govan J.R.W. Glass S. The microbiology and therapy of cystic fibrosis lung infections Rev. Med. Microbiol. 1 1990 19-28
67. Moller L.V. Timens W. van der Bij W. Kooi K. de Wever B. Dankert J. et al. Haemophilus influenzae in lung explants of patients with end-stage pulmonary disease Am. J. Respir. Crit. Care Med. 157 1998 950-956
68. van Schilfgaarde M. Eijk P. Regelink A. van Ulsen P. Everts V. Dankert J. et al. Haemophilus influenzae localized in epithelial cell layers is shielded from antibiotics and antibody-mediated bactericidal activity Microb. Pathog. 26 1999 249-262
69. Coenye T. Vandamme P. Govan J.R.W. LiPuma J.J. Taxonomy and identification of the Burkholderia cepacia complex J. Clin. Microbiol. 39 2001 3427-3436
70. Vandamme P. Henry D. Coenye T. Nzula S. Vancanneyt M. LiPuma J.J. et al. Burkholderia anthina sp. nov. and Burkholderia pyrrocinia, two additional Burkholderia cepacia complex bacteria, may confound results of new molecular diagnostic tools FEMS Immunol. Med. Microbiol. 33 2002 143-149
71. Vandamme P. Holmes B. Conye T. Goris J. Mahenthiralingam E. LiPuma J.J. et al. Burkholderia cenocepacia sp. nov.-a new twist to an old story Res. Microbiol. 154 2003 91-96
72. Tablan O.C. Martone W.J. Doershuk C.F. Stern R.C. Thomassen M.J. Klinger J.D. et al. Colonization of the respiratory tract with Pseudomonas cepacia in cystic fibrosis. Risk factors and outcomes Chest 91 1987 527-532
73. Gladman G. Connor P.J. Williams R.F. David T.J. Controlled study of Pseudomonas cepacia and Pseudomonas maltophilia in cystic fibrosis Arch. Dis. Child. 67 1992 192-195
74. Karpati F. Malmborg A.S. Alfredsson H. Hjelte L. Strandvik B. Bacterial colonization with Xanthomonas maltophilia-a retrospective study in a cystic fibrosis patient population Infection 22 1994 258-263
75. Goss C.H. Aitken M.L. Otto K. Rubenfeld G.D. Acquiring Stenotrophomonas maltophilia does not reduce survival in patients with cystic fibrosis Am. J. Respir. Crit. Care Med. 166 2002 356-361
76. Demko C.A. Stern R.C. Doershuk C.F. Stenotrophomonas maltophilia in cystic fibrosis: incidence and prevalence Pediatr. Pulmonol. 25 1998 304-308
77. Denton M. Kerr K.G. Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia Clin. Microbiol. Rev. 11 1998 57-80
78. Talmaciu I. Varlotta L. Mortensen J. Schidlow D.V. Risk factors for emergence of Stenotrophomonas maltophilia in cystic fibrosis Pediatr. Pulmonol. 30 2000 10-15
79. Dunne W.M.Jr. Maisch S. Epidemiological investigation of infections due to Alcaligenes species in children and patients with cystic fibrosis: use of repetitive-element-sequence polymerase chain reaction Clin. Infect. Dis. 20 1995 836-841
80. Olivier K.N. Weber D.J. Lee J.H. Handker A. Tudor G. Molina P.L. et al. Nontuberculous mycobacteria Am. J. Respir. Crit. Care Med. 167 2003 835-840
81. Tomashefski J.F.Jr. Stern R.C. Demko C.A. Doershuk C.F. Nontuberculous mycobacteria in cystic fibrosis. An autopsy study Am. J. Respir. Crit. Care Med. 154 1996 523-528
82. Cullen A.R. Cannon C.L. Mark E.J. Colin A.A. Mycobacterium abscessus infection in cystic fibrosis. Colonization or infection? Am. J. Respir. Crit. Care Med. 161 2000 641-645
83. Fauroux B. Delaisi B. Clement A. Saizon C. Moissenet D. Truffot-Pernot C. et al. Mycobacterial lung disease in cystic fibrosis: a prospective study Pediatr. Infect. Dis. J. 16 1997 354-358
84. Oermann C.M. Starke J.R. Seilheimer D.K. Pulmonary disease caused by Mycobacterium kansasii in a patient with cystic fibrosis Pediatr. Infect. Dis. J. 16 1997 257-259
85. Oliver A. Maiz L. Canton R. Escobar H. Vaquero F. Gomez-Mampaso E. Nontuberculous mycobacteria in patients with cystic fibrosis Clin. Infect. Dis. 32 2001 1298-1303
86. Nikolaizik W.H. Moser M. Crameri R. Little S. Warner J.O. Blaser K. et al. Identification of allergic bronchopulmonary aspergillosis in cystic fibrosis patients by recombinant Aspergillus fumigatus I/a-specific serology Am. J. Respir. Crit. Care Med. 152 1995 634-639
87. Geller D.E. Kaplowitz H. Light M.J. Colin A.A. Allergic bronchopulmonary aspergillosis in cystic fibrosis: reported prevalence, regional distribution, and patient characteristics. Scientific Advisory Group, Investigators, and Coordinators of the Epidemiologic Study of Cystic Fibrosis Chest 116 1999 639-646
88. Mastella G. Rainisio M. Harms H.K. Hodson M.E. Koch C. Navarro J. et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis. A European epidemiological study. Epidemiologic Registry of Cystic Fibrosis Eur. Respir. J. 16 2000 464-471
89. Maguire C.P. Hayes J.P. Hayes M. Masterson J. FitzGerald M.X. Three cases of pulmonary Aspergilloma in adult patients with cystic fibrosis Thorax 50 1995 805-806
90. Brown K. Rosenthal M. Bush A. Fatal invasive aspergillosis in an adolescent with cystic fibrosis Pediatr. Pulmonol. 27 1999 130-133
91. Wang E.E. Prober C.G. Manson B. Corey M. Levison H. Association of respiratory viral infections with pulmonary deterioration in patients with cystic fibrosis N. Engl. J. Med. 311 1984 1653-1658
92. Abman S.H. Ogle J.W. Butler-Simon N. Rumack C.M. Accurso F.J. Role of respiratory syncytial virus in early hospitalizations for respiratory distress of young infants with cystic fibrosis J. Pediatr. 113 1988 826-830
93. Ramsey B.W. Gore E.J. Smith A.L. Cooney M.K. Redding G.J. Foy H. The effect of respiratory viral infections on patients with cystic fibrosis Am. J. Dis. Child. 143 1989-662 668
94. Pribble C.G. Black P.G. Bosso J.A. Turner R.B. Clinical manifestations of exacerbations of cystic fibrosis associated with nonbacterial infections J. Pediatr. 117 1990 200-204
95. Armstrong D. Grimwood K. Carlin J.B. Carzino R. Hull J. Olinsky A. et al. Severe viral respiratory infections in infants with cystic fibrosis Pediatr. Pulmonol. 26 1998 371-379
96. Hiatt P.W. Grace S.C. Kozinetz C.A. Raboudi S.H. Treece D.G. Taber L.H. et al. Effects of viral lower respiratory tract infection on lung function in infants with cystic fibrosis Pediatrics 103 1999 619-626
97. Petersen N.T. Høiby N. Mordhorst C.H. Lind K. Flensborg E.W. Bruun B. Respiratory infections in cystic fibrosis patients caused by virus, chlamydia and mycoplasma-possible synergism with Pseudomonas aeruginosa Acta Paediatr. Scand. 70 1981 623-628
98. Ferson M.J. Morton J.R. Robertson P.W. Impact of influenza on morbidity in children with cystic fibrosis J. Paediatr. Child Health 27 1991 308-311
99. Conway S.P. Simmonds E.J. Littlewood J.M. Acute severe deterioration in cystic fibrosis associated with influenza A virus infection Thorax 47 1992 112-114
100. Johansen H.K. Høiby N. Seasonal onset of initial colonisation and chronic infection with Pseudomonas aeruginosa in patients with cystic fibrosis in Denmark Thorax 47 1992 109-111
101. Frederiksen B. Koch C. Høiby N. Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis Pediatr. Pulmonol. 23 1997 330-335
102. Nixon G.M. Armstrong D.S. Carzino R. Carlin J.B. Olinsky A. Robertson C.F. et al. Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis J. Pediatr. 138 2001 699-704
103. Ratjen F. Döring G. Nikolaizik W. Eradication of Pseudomonas aeruginosa with inhaled tobramycin in patients with cystic fibrosis Lancet 358 2001 983-984
104. Valerius N.H. Koch C. Høiby N. Prevention of chronic Pseudomonas aeruginosa colonization in cystic fibrosis by early treatment Lancet 338 1991 672-725
105. Wiesemann H.G. Steinkamp G. Ratjen F. Bauernfeind A. Przyklenk B. Döring G. et al. Placebo controlled, double blind, randomized study of aerosolized tobramycin for early treatment of Pseudomonas aeruginosa colonization in patients with cystic fibrosis Pediatr. Pulmonol. 25 1998 88-92
106. Govan J.R. Deretic V. Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia Microbiol. Rev. 60 1996 539-574
107. Worlitzsch D. Tarran R. Ulrich M. Schwab U. Cekici A. Meyer K.C. et al. Reduced oxygen concentrations in airway mucus contribute to the early and late pathogenesis of Pseudomonas aeruginosa cystic fibrosis airways infection J. Clin. Invest. 109 2002 317-325
108. Mathee K. Ciofu O. Sternberg C. Lindum P.W. Campbell J. Jensen P. et al. Mucoid conversion of Pseudomonas aeruginosa by hydrogen peroxide: a mechanism for virulence activation in the cystic fibrosis lung Microbiology 145 1999 1349-1357
109. Walters M.C.III Roe F. Bugnicourt A. Franklin M.J. Stewart P.S. Contributions of antibiotic penetration, oxygen limitation, and low metabolic activity to tolerance of Pseudomonas aeruginosa biofilms to ciprofloxacin and tobramycin Antimicrob. Agents Chemother. 47 2003 317-323
110. Govan J.R.W. Nelson J.W. Microbiology of cystic fibrosis lung infections: themes and issues J. R. Soc. Med. 86 1993 11-18 [suppl.]
111. McKenney D. Tibbetts K.L. Wang Y. Murthy V. Ulrich M. Döring G. et al. Broadly-protective vaccine for Staphylococcus aureus based on an in vivo expressed antigen Science 284 1999 1523-1527
112. Cramton S.E. Ulrich M. Götz F. Döring G. Anaerobic conditions induce expression of the polysaccharide intercellular adhesin in Staphylococcus aureus and Staphylococcus epidermidis Infect. Immun. 69 2001 4079-4085
113. Bardouniotis E. Ceri H. Olson M.E. Biofilm formation and biocide susceptibility testing of Mycobacterium fortuitum and Mycobacterium marinum Curr. Microbiol. 46 2003 28-32
114. Nickel J.C. Ruseska I. Wright J.B. Costerton J.W. Tobramycin resistance of Pseudomonas aeruginosa cells growing as a biofilm on urinary catheter material Antimicrob. Agents Chemother. 27 1985 619-624
115. Shawar R.M. MacLeod D.L. Garber R.L. Burns J.L. Stapp J.R. Clausen C.R. et al. Activities of tobramycin and six other antibiotics against Pseudomonas aeruginosa isolates from patients with cystic fibrosis Antimicrob. Agents Chemother. 43 1999 2877-2880
116. Oliver A. Canton R. Campo P. Baquero F. Blazquez J. High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection Science 288 2000 1251-1254
117. Oliver A. Baquero F. Blazquez J. The mismatch repair system (mutS, mutL and uvrD genes) in Pseudomonas aeruginosa: molecular characterization of naturally occurring mutants Mol. Microbiol. 43 2002 1641-1650
118. Levy J. Antibiotic activity in sputum J. Pediatr. 108 1986 841-846
119. Littlewood J.M. Miller M.G. Ghoneim A.T.M. Ramsden C.H. Nebulised colomycin for early pseudomonas colonisation in cystic fibrosis Lancet i 1985 865
120. Frederiksen B. Koch C. Høiby N. Changing epidemiology of Pseudomonas aeruginosa infection in Danish cystic fibrosis patients (1974-1995) Pediatr. Pulmonol. 8 1999 59-66
121. Gibson R.L. Emerson J. McNamara S. Burns J.L. Rosenfeld M. Yunker A. et al. Cystic Fibrosis Therapeutics Development Network Study Group. Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis Am. J. Respir. Crit. Care Med. 167 2003 841-849
122. Gibson R.L. Emerson J. McNamara S. Burns J.L. Rosenfeld M. Yunker A. et al. Cystic Fibrosis Therapeutics Development Network Study Group. Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis Am. J. Respir. Crit. Care Med. 167 2003 841-849
123. Munck A. Bonacorsi S. Mariani-Kurkdjian P. Lebourgeois M. Gerardin M. Brahimi N. et al. Genotypic characterization of Pseudomonas aeruginosa strains recovered from patients with cystic fibrosis after initial and subsequent colonization Pediatr. Pulmonol. 32 2001 288-292
124. Baumann U. Stocklassa C. Greiner W. Graf von der Schulenburg J.-M. von der Mordt H. Costs of care and clinical conditions in paediatric cystic fibrosis patients J. Cystic Fibrosis 2 2003 84-90
125. Elborn J.S. Treatment of Staphylococcus aureus in cystic fibrosis Thorax 54 1999 377-378
126. Goerke C. Kraning K. Stern M. Döring G. Botzenhart K. Wolz C. Molecular epidemiology of community-acquired Staphylococcus aureus in families with and without cystic fibrosis patients J. Infect. Dis. 181 2000 984-989
127. Szaff M. Høiby N. Antibiotic treatment of Staphylococcus aureus infection in cystic fibrosis Acta Paediatr. Scand. 71 1982 21-26
128. Nepomuceno I.B. Esrig S. Moss R.B. Allergic bronchopulmonary aspergillosis in cystic fibrosis: role of atopy and response to itraconazole Chest 115 1999 364-370
129. Skov M. Høiby N. Koch C. Itraconazole treatment of allergic bronchopulmonary aspergillosis in patients with cystic fibrosis Allergy 57 2002 723-728
130. Kosorok M.R. Jalaluddin M. Farrell P.M. Shen G. Colby C.E. Laxova A. et al. Comprehensive analysis of risk factors for acquisition of Pseudomonas aeruginosa in young children with cystic fibrosis Pediatr. Pulmonol. 26 1998 81-88
131. Weaver L.T. Green M.R. Nicholson K. Mills J. Heeley M.E. Kuzemko J.A. et al. Prognosis in cystic fibrosis treated with continuous flucloxacillin from the neonatal period Arch. Dis. Child. 70 1994 84-89
132. Ratjen F. Comes G. Paul K. Posselt H.G. Wagner T.O. Harms K. Effect of continuous anti-staphylococcal therapy on the rate of P. aeruginosa acquisition in patients with cystic fibrosis Pediatr. Pulmonol. 31 2001 13-16
133. Stutman H.R. Lieberman J.M. Nussbaum E. Marks M.I. Antibiotic prophylaxis in infants and young children with cystic fibrosis: a randomized controlled trial J. Pediatr. 140 2002 299-305
134. Demko C.A. Byard P.J. Davis P.B. Gender differences in cystic fibrosis: Pseudomonas aeruginosa infection J. Clin. Epidemiol. 48 1995 1041-1049
135. Birrer P. McElvaney N.G. Rudeberg A. Sommer C.W. Liechti-Gallati S. Kraemer R. et al. Protease-antiprotease imbalance in the lungs of children with cystic fibrosis Am. J. Respir. Crit. Care Med. 150 1994 207-213
136. Cantin A. Cystic fibrosis lung inflammation: early, sustained and severe Am. J. Respir. Crit. Care Med. 151 1995 939-941
137. Elborn J.S. Cordon S.M. Western P.J. Macdonald I.A. Shale D.J. Tumour necrosis factor-alpha, resting energy expenditure and cachexia in cystic fibrosis Clin. Sci. (Lond.) 85 1993 563-568
138. Moldawer L.L. Copel E.M.III Proinflammatory cytokines, nutritional support, and the cachexia syndrome: interactions and therapeutic options Cancer 79 1997 1828-1839
139. Bonfield T.L. Panuska J.R. Konstan M.W. Hilliard K.A. Hilliard J.B. Ghnaim H. et al. Inflammatory cytokines in cystic fibrosis lungs Am. J. Respir. Crit. Care Med. 152 1995 2111-2118
140. Meyer K.C. Zimmerman J. Neutrophil mediators, Pseudomonas, and pulmonary dysfunction in cystic fibrosis J. Lab. Clin. Med. 121 1993 654-661
141. Quan J.M. Tiddens H.A. Sy J.P. McKenzie S.G. Montgomery M.D. Robinson P.J. et al. A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities. The Pulmozyme Early Intervention Trial Study Group J. Pediatr. 139 2001 813-820
142. Bell S.C. Bowerman A.M. Nixon L.E. Macdonald I.A. Elborn J.S. Shale D.J. Metabolic and inflammatory responses to pulmonary exacerbation in adults with cystic fibrosis Eur. J. Clin. Invest. 30 2000 553-559
143. Tiddens H.A. Detecting early structural lung damage in cystic fibrosis Pediatr. Pulmonol. 34 2002 228-231
144. Willmott R.W. Kassab J.T. Kilian P.L. Benjamin W.R. Douglas S.D. Wood R.E. Increased levels of interleukin-1 in bronchoalveolar washings from children with bacterial pulmonary infections Am. Rev. Respir. Dis. 142 1990 365-368
145. Noah T.L. Black H.R. Cheng P.W. Wood R.E. Leigh M.W. Nasal and bronchoalveolar lavage fluid cytokines in early cystic fibrosis J. Infect. Dis. 175 1997 638-647
146. Hull J. Vervaard P. Gromwood K. Phelan P. Pulmonary oxidative stress response in young children with cystic fibrosis Thorax 52 1997 557-560
147. Hunt J. Exhaled breath condensate: an evolving tool for noninvasive evaluation of lung disease J. Allergy Clin. Immunol. 110 2002 28-34
148. Worlitzsch D. Herberth G. Ulrich M. Döring G. Catalase, myeloperoxidase and hydrogen peroxide in cystic fibrosis Eur. Respir. J. 11 1998 377-383
149. Gabbay E. Fisher A.J. Small T. Leonard A.J. Corris P.A. Exhaled single-breath nitric oxide measurements are reproducible, repeatable and reflect levels of nitric oxide found in the lower airways Eur. Respir. J. 11 1998 467-472
150. Montuschi P. Kharitonov S.A. Ciabattoni G. Corradi M. van Rensen L. Geddes D.M. et al. Exhaled 8-isoprostane as a new non-invasive biomarker of oxidative stress in cystic fibrosis Thorax 55 2000 205-209
151. McGrath L.T. Patrick R. Mallon P. Dowey L. Silke B. Norwood W. et al. Breath isoprene during acute respiratory exacerbation in cystic fibrosis Eur. Respir. J. 16 2000 1065-1069
152. Auerbach H.S. Williams M. Kirkpatrick J.A. Colton H.R. Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis Lancet 2 1985 686-688
153. Rosenstein B.J. Eigen H. Risks of alternate-day prednisone in patients with cystic fibrosis Pediatrics 87 1990 245-246
154. Lai H.C. FitzSimmons S.C. Allen D.B. Kosorok M.R. Rosenstein B.J. Campbell P.W. et al. Risk of persistent growth impairment after alternate-day prednisone treatment in children with cystic fibrosis N. Engl. J. Med. 342 2000 851-859
155. Greally P. Hussain M.J. Vergani D. Price J.F. Interleukin-1 alpha, soluble interleukin-2 receptor, and IgG concentrations in cystic fibrosis treated with prednisolone Arch. Dis. Child. 71 1994 35-39
156. Bisgaard H. Pedersen S.S. Nielsen K.G. Skov M. Laursen E.M. Kronborg G. et al. Controlled trial of inhaled budesonide in patients with cystic fibrosis and chronic bronchopulmonary Pseudomonas aeruginosa infection Am. J. Respir. Crit. Care Med. 156 1997 1190-1196
157. van Haren E.H. Lammers J.W. Festen J. Heijerman H.G. Groot C.A. van Herwaarden C.L. The effects of the inhaled corticosteroid budesonide on lung function and bronchial hyperresponsiveness in adult patients with cystic fibrosis Respir. Med. 89 1995 209-214
158. Nikolaizik W.H. Schoni M.H. Pilot study to assess the effect of inhaled corticosteroids on lung function in patients with cystic fibrosis J. Pediatr. 128 1996 271-274
159. Balfour-Lynn I.M. Klein N.J. Dinwiddie R. Randomised controlled trial of inhaled corticosteroids (fluticasone propionate) in cystic fibrosis Arch. Dis. Child. 77 1997 124-130
160. Skov M. Main K.M. Sillesen I.B. Muller J. Koch C. Lanng S. Iatrogenic adrenal insufficiency as a side-effect of combined treatment of itraconazole and budesonide Eur. Respir. J. 20 2002 127-133
161. Main K.M. Skov M. Sillesen I.B. Digepedersen H. Muller J. Koch C. et al. Cushing's syndrome due to pharmacological interaction in a cystic fibrosis patient Acta Paediatr. 91 2002 1008-1011
162. Konstan M.W. Hoppel C.L. Chai B.-L. Davis P.B. Ibuprofen in children with cystic fibrosis: pharmacokinetics and adverse effects J. Pediatr. 118 1991 956-964
163. Konstan M.W. Byard P.J. Hoppel C.L. Davis P.B. Effect of high-dose ibuprofen in patients with cystic fibrosis N. Engl. J. Med. 332 1995 848-854
164. Birke F.W. Meade C.J. Anderskewitz R. Speck G.A. Jennewein H.M. In vitro and in vivo pharmacological characterization of BIIL 284, a novel and potent leukotriene B(4) receptor antagonist J. Pharmacol. Exp. Ther. 297 2001 458-466
165. Johansen H.K. Hougen H.P. Rygaard J. Høiby N. Interferon-gamma (IFN-gamma) treatment decreases the inflammatory response in chronic Pseudomonas aeruginosa pneumonia in rats Clin. Exp. Immunol. 103 1996 212-218
166. Pierangeli S.S. Polk H.C.Jr. Parmely M.J. Sonnenfeld G. Murine interferon-gamma enhances resistance to infection with strains of Pseudomonas aeruginosa in mice Cytokine 5 1993 230-234
167. McElvaney N.G. Nakamura H. Birrer P. Hebert C.A. Wong W.L. Alphonso M. et al. Modulation of airway inflammation in cystic fibrosis. In vivo suppression of interleukin-8 levels on the respiratory epithelial surface by aerosolization of recombinant secretory leukoprotease inhibitor J. Clin. Invest. 90 1992 1296-1301
168. McElvaney N.G. Doujaiji B. Moan M.J. Burnham M.R. Wu M.C. Crystal R.G. Pharmacokinetics of recombinant secretory leukoprotease inhibitor aerosolized to normals and individuals with cystic fibrosis Am. Rev. Respir. Dis. 148 1993 1056-1060
169. McElvaney N.G. Hubbard R.C. Birrer P. Chernick M.S. Caplan D.B. Frank M.M. et al. Aerosol a1-antitrypsin treatment for cystic fibrosis Lancet 337 1991 392-394
170. Gershon D. Will milk shake up industry? Nature 353 1991-7
171. Wolter J. Seeney S. Bell S. Bowler S. Masel P. McCormack J. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial Thorax 57 2002 212-216
172. Equi A. Balfour-Lynn I.M. Bush A. Rosenthal M. Long term azithromycin in children with cystic fibrosis: a randomized, placebo-controlled crossover trial Lancet 360 2002 978-984
173. Garey K.W. Alwani A. Danziger L.H. Rubinstein I. Tissue reparative effects of macrolide antibiotics in chronic inflammatory sinopulmonary diseases Chest 123 2003 261-265
174. Ilowite J.S. Gorvoy J.D. Smaldone G.C. Quantitative deposition of aerosolized gentamicin in cystic fibrosis Am. Rev. Respir. Dis. 136 1987 1445-1449
175. Stafanger G. Koch C. N-acetylcysteine in cystic fibrosis and Pseudomonas aeruginosa infection: clinical score, spirometry and ciliary motility Eur. Respir. J. 2 1989 234-237
176. Shak S. Capon D.J. Hellmiss R. Marsters S.A. Baker C.L. Recombinant human DNAse I reduces the viscosity of cystic fibrosis sputum Proc. Natl. Acad. Sci. U. S. A. 87 1990 188-192
177. Hodson M.E. Aerosolized dornase alfa (rhDNase) for therapy of cystic fibrosis Am. J. Respir. Crit. Care Med. 151 1995 S70-S74
178. Fuchs H.J. Borowitz D.S. Christiansen D.H. Morris E.M. Nash M.L. Ramsey B.W. et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis N. Engl. J. Med. 331 1994 637-642
179. Harms H.K. Matouk E. Tournier G. von der Hardt H. Weller P.H. Romano L. et al. Multicenter, open-label study of recombinant human DNase in cystic fibrosis patients with moderate lung disease. DNase International Study Group Pediatr. Pulmonol. 26 1998 155-161
180. Whitchurch C.B. Tolker-Nielsen T. Ragas P.C. Mattick J.S. Extracellular DNA required for bacterial biofilm formation Science 295 2002-1487
181. Frederiksen B. Koch C. Høiby N. Pressler T. Hansen A. Effect of aerosolized rhDNase (pulmozyme) on pulmonary infections in CF: an open randomized study Pediatr. Pulmonol. Suppl. 20 2000 247 [Abstract 260]
182. Alfredsson H. Malmborg A.S. Strandvik B. N-acetylcysteine and 2-mercaptoethane sulphonate inhibit anti-pseudomonas activity of antibiotics in vitro Eur. J. Respir. Dis. 70 1987 213-217
183. Hunt B.E. Weber A. Berger A. Ramsey B. Smith A.L. Macromolecular mechanisms of sputum inhibition of tobramycin activity Antimicrob. Agents Chemother. 39 1995 34-39
184. Sajjan U.S. Tran L.H. Sole N. Rovaldi C. Akiyama A. Friden P.M. et al. P-113D, an antimicrobial peptide active against Pseudomonas aeruginosa, retains activity in the presence of sputum from cystic fibrosis patients Antimicrob. Agents Chemother. 45 2001 3437-3444
185. Sanders N.N. De Smedt S.C. Van Rompaey E. Simoens P. De Baets F. Demeester J. Cystic fibrosis sputum: a barrier to the transport of nanospheres Am. J. Respir. Crit. Care Med. 162 2000 1905-1911
186. Sanders N.N. Van Rompaey E. De Smedt S.C. Demeester J. On the transport of lipoplexes through cystic fibrosis sputum Pharm. Res. 19 2002 451-456
187. Stern M. Caplen N.J. Browning J.E. Griesenbach U. Sorgi F. Huang L. et al. The effect of mucolytic agents on gene transfer across a CF sputum barrier in vitro Gene Ther. 5 1998 91-98
188. Cantin A.M. DNase I acutely increases cystic fibrosis sputum elastase activity and its potential to induce lung hemorrhage in mice Am. J. Respir. Crit. Care Med. 157 1998 464-469
189. Hansen G. Hoffjan S. Mosler K. Schuster A. Effect of recombinant human DNase on alpha1-proteinase inhibitor function: an experimental approach to the combined clinical use of rhDNase and alpha1-PI in CF patients Lung 179 2001 185-194
190. Suri R. Marshall L.J. Wallis C. Metcalfe C. Bush A. Shute J.K. Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis Am. J. Respir. Crit. Care Med. 166 2002 352-355
191. Shah P.L. Scott S.F. Knight R.A. Hodson M.E. The effects of recombinant human DNase on neutrophil elastase activity and interleukin-8 levels in the sputum of patients with cystic fibrosis Eur. Respir. J. 9 1996 531-534
192. Costello C.M. O'Connor C.M. Finlay G.A. Shiels P. FitzGerald M.X. Hayes J.P. Effect of nebulised recombinant DNase on neutrophil elastase load in cystic fibrosis Thorax 51 1996 619-623
193. Robinson M. Hemming A.L. Regnis J.A. Wong A.G. Bailey D.L. Bautovich G.J. et al. Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis Thorax 52 1997 900-903
194. Suri R. Metcalfe C. Lees B. Grieve R. Flather M. Normand C. et al. Comparison of hypertonic saline and alternate-day or daily recombinant human deoxyribonuclease in children with cystic fibrosis: a randomised trial Lancet 358 2001 1316-1321
195. von Eiff C. Becker K. Machka K. Stammer H. Peters G. Nasal carriage as a source of Staphylococcus aureus bacteremia. Study Group N. Engl. J. Med. 344 2001 11-16
196. Branger C. Gardye C. Lambert-Zechovsky N. Persistence of Staphylococcus aureus strains among cystic fibrosis patients over extended periods of time J. Med. Microbiol. 45 1996 294-301
197. Bell S.M. Recommendations for control of the spread of methicillin-resistant Staphylococcus aureus infection based on 18 years' experience in a group of teaching hospitals Med. J. Aust. 1 1982 472-474
198. Givney R. Vickery A. Holliday A. Pegler M. Benn R. Methicillin-resistant Staphylococcus aureus in a cystic fibrosis unit J. Hosp. Infect. 35 1997 27-36
199. Mitcherlich E. Marth E.H. Microbial survival in the environment 1984 Springer Berlin
200. Botzenhart K. Döring G. Epidemiology and ecology of Pseudomonas aeruginosa In: Campa M. Bendinelli M. Friedman H. (Eds.) Pseudomonas aeruginosa as an opportunistic pathogen 1993 1-18 Plenum New York
201. Döring G. Ulrich M. Müller W. Bitzer J. Schmidt-Koenig L. Münst L. et al. Generation of Pseudomonas aeruginosa aerosols during handwashing from contaminated sink drains, transmission to hands of hospital personnel, and its prevention by use of a new heating device Zentralbl. Hyg. 191 1991 494-505
202. Döring G. Jansen S. Noll J. Grupp H. Frank F. Botzenhart K. et al. Distribution and transmission of Pseudomonas aeruginosa and Burkholderia cepacia in a hospital ward Pediatr. Pulmonol. 21 1996 90-100
203. Zimakoff J. Høiby N. Rosendal K. Guilbert J.P. Epidemiology of Pseudomonas aeruginosa infection and the role of contamination of the environment in a cystic fibrosis clinic J. Hosp. Infect. 4 1983 31-40
204. Hentges D.J. Stein A.J. Casey S.W. Que J.U. Protective role of intestinal flora against infection with Pseudomonas aeruginosa in mice: influence of antibiotics on colonization resistance Infect. Immun. 47 1985 118-122
205. Bosshammer J. Fiedler B. Gudowius P. von der Hardt H. Romling U. Tummler B. Comparative hygienic surveillance of contamination with pseudomonads in a cystic fibrosis ward over a 4-year period J. Hosp. Infect. 31 1995 261-274
206. Pitchford K.C. Corey M. Highsmith A.K. Perlman R. Bannatyne R. Gold R. et al. Pseudomonas species contamination of cystic fibrosis patients' home inhalation equipment J. Pediatr. 111 1987 212-216
207. Rosenfeld M. Emerson J. Astley S. Joy P. Williams-Warren J. Standaert T.A. et al. Home nebulizer use among patients with cystic fibrosis J. Pediatr. 132 1998 125-131
208. Jakobsson B.M. Onnered A.B. Hjelte L. Nystrom B. Low bacterial contamination of nebulizers in home treatment of cystic fibrosis patients J. Hosp. Infect. 36 1997 201-207
209. Jensen E.T. Giwercman B. Ojeniyi B. Bangsborg J.M. Hansen A. Koch C. et al. Epidemiology of Pseudomonas aeruginosa in cystic fibrosis and the possible role of contamination by dental equipment J. Hosp. Infect. 36 1997 117-122
210. Halabi M. Wiesholzer-Pittl M. Schoberl J. Mittermayer H. Non-touch fittings in hospitals: a possible source of Pseudomonas aeruginosa and Legionella spp. J. Hosp. Infect. 49 2001 117-121
211. Worlitzsch D. Wolz C. Botzenhart K. Hansis M. Burgdörfer H. Ogle J.W. et al. Molecular epidemiology of Pseudomonas aeruginosa urinary tract infections in paraplegic patients Zentralbl. Hyg. 189 1989 175-184
212. Kerr J.R. Moore J.E. Curran M.D. Graham R. Webb C.H. Lowry K.G. et al. Investigation of a nosocomial outbreak of Pseudomonas aeruginosa pneumonia in an intensive care unit by random amplification of polymorphic DNA assay J. Hosp. Infect. 30 1995 125-131
213. Orsi G.B. Mansi A. Tomao P. Chiarini F. Visca P. Lack of association between clinical and environmental isolates of Pseudomonas aeruginosa in hospital wards J. Hosp. Infect. 27 1994 49-60
214. Govan J.R. Nelson J.W. Microbiology of lung infection in cystic fibrosis Br. Med. Bull. 48 1992 912-930
215. Hollyoak V. Allison D. Summers J. Pseudomonas aeruginosa wound infection associated with a nursing home's whirlpool bath Commun. Dis. Rep. CDR Rev. 5 1995 R100-R102
216. Ruschke R. Kunststoff-Schwimmtiere als Biotope für Mikroorganismen und mögliche Infektionsquellen für Kleinkinder Zentralbl. Bakteriol., Abt. 1, Orig. B 163 1976 556-564
217. Barbeau J. Tanguay R. Faucher E. Avezard C. Trudel L. Côté L. et al. Multiparametric analysis of waterline contamination in dental units Appl. Environ. Microbiol. 62 1996 3954-3959
218. Barbeau J. ten-Bokum L. Gauthier C. Prevost A.P. Cross-contamination potential of saliva ejectors used in dentistry J. Hosp. Infect. 40 1998 303-311
219. Handel G. Zur Problematik der Kontamination zahnärztlicher Behandlungseinheiten mit Pseudomonas aeruginosa insbesondere für Mukoviszidose-Patienten. Dissertation. Univ. Tübingen; (1994).
220. Speert D.P. Campbell M.E. Hospital epidemiology of Pseudomonas aeruginosa from patients with cystic fibrosis J. Hosp. Infect. 9 1987 11-21
221. Jones A.M. Govan J.R.W. Dohorty C.J. Dodd M.E. Isalska B.J. Stanbridge T.N. et al. Identification of airborne dissemination of epidemic multiresistant strains of P. aeruginosa at a CF centre during a crossinfection outbreak Thorax 58 2003 525-527
222. Remington J.S. Schimpff S.C. Occasional notes. Please don't eat the salads N. Engl. J. Med. 304 1981 433-435
223. Parke J.L. Gurian-Sherman D. Diversity of the Burkholderia cepacia complex and implications for risk assessment of biological control strains Annu. Rev. Phytopathol. 39 2001 225-258
224. Carson L.A. Tablan O.C. Cusick L.B. Jarvis W.R. Favero M.S. Bland L.A. Comparative evaluation of selective media for isolation of Pseudomonas cepacia from cystic fibrosis patients and environmental sources J. Clin. Microbiol. 26 1988 2096-2100
225. Butler S.L. Doherty C.J. Hughes J.E. Nelson J.W. Govan J.R. Burkholderia cepacia and cystic fibrosis: do natural environments present a potential hazard? J. Clin. Microbiol. 33 1995 1001-1004
226. Balandreau J. Viallard V. Cournoyer B. Coenye T. Laevens S. Vandamme P. Burkholderia cepacia genomovar III is a common plant-associated bacterium Appl. Environ. Microbiol. 67 2001 982-985
227. Cazzola G. Amalfitano G. Tonolli E. Perazzoli C. Piacentini I. Mastella G. Burkholderia (Pseudomonas) cepacia epidemiology in a cystic fibrosis population: a genome finger-printing study Acta Paediatr. 85 1996 554-557
228. Govan J.R. Brown P.H. Maddison J. Doherty C.J. Nelson J.W. Dodd M. et al. Evidence for transmission of Pseudomonas cepacia by social contact in cystic fibrosis Lancet 342 1993 15-19
229. LiPuma J.J. Dasen S.E. Nielson D.W. Stern R.C. Stull T.L. Person-to-person transmission of Pseudomonas cepacia between patients with cystic fibrosis Lancet 336 1990 1094-1096
230. LiPuma J.J. Spilker T. Gill L.H. Campbell P.W.III Liu L. Mahenthiralingam E. Disproportionate distribution of Burkholderia cepacia complex species and transmissibility markers in cystic fibrosis Am. J. Respir. Crit. Care Med. 164 2001 92-96
231. Mahenthiralingam E. Vandamme P. Campbell M.E. Henry D.A. Gravelle A.M. Wong L.T.K. et al. Infection with Burkholderia cepacia complex genomovars in patients with cystic fibrosis: virulent transmissible strains of genomovar III can replace B. multivorans Clin. Infect. Dis. 33 2001 1469-1475
232. LiPuma J.J. Spilker T. Coenye T. Gonzalez C.F. An epidemic Burkholderia cepacia complex strain identified in soil Lancet 359 2002 2002-2003
233. Liu L. Spilker T. Coenye T. LiPuma J.J. Identification by subtractive hybridization of a novel insertion element specific for two widespread Burkholderia cepacia genomovar III strains J. Clin. Microbiol. 41 2003 2471-2476
234. Govan J.R.W. Balandreau J. Vandamme P. Burkholderia cepacia-friend and foe ASM News 66 2000 124-125
235. Holmes A. Govan J. Goldstein R. Agricultural use of Burkholderia (Pseudomonas) cepacia: a threat to human health? Emerg. Infect. Dis. 4 1998 221-227
236. Mortensen J.E. Fisher M.C. LiPuma J.J. Recovery of Pseudomonas cepacia and other Pseudomonas species from the environment Infect. Control Hosp. Epidemiol. 16 1995 30-32
237. Reboli A.C. Koshinski R. Arias K. Marks-Austin K. Stieritz D. Stull T.L. An outbreak of Burkholderia cepacia lower respiratory tract infection associated with contaminated albuterol nebulization solution Infect. Control Hosp. Epidemiol. 17 1996 741-743
238. Martone W.- Tablan O.C. Jarvis W.R. The epidemiology of nosocomial epidemic Pseudomonas cepacia infections Eur. J. Epidemiol. 3 1987 222-232
239. Hyde J. Humphreys H. Absence of Burkholderia cepacia from the respiratory tract of non-cystic fibrosis patients Eur. J. Clin. Microbiol. Infect. Dis. 16 1997 253-254
240. Drabick J.A. Gracely E.J. Heidecker G.J. LiPuma J.J. Survival of Burkholderia cepacia on environmental surfaces J. Hosp. Infect. 32 1996 267-276
241. Ensor E. Humphreys H. Peckham D. Webster C. Knox A.J. Is Burkholderia (Pseudomonas) cepacia disseminated from cystic fibrosis patients during physiotherapy? J. Hosp. Infect. 32 1996 9-15
242. McMenamin J.D. Zaccone T.M. Coenye T. Vandamme P. LiPuma J.J. Misidentification of Burkholderia cepacia in US cystic fibrosis treatment centers: an analysis of 1,051 recent sputum isolates Chest 117 2000 1661-1665
243. Liu L. Coenye T. Burns J.L. Whitby P.W. Stull T.L. LiPuma J.J. Ribosomal DNA-directed PCR for identification of Achromobacter (Alcaligenes) xylosoxidans recovered from sputum samples from cystic fibrosis patients J. Clin. Microbiol. 40 2002 1210-1213
244. Verweij P.E. Meis J.F. Christmann V. Van der Bor M. Melchers W.J. Hilderink B.G. et al. Nosocomial outbreak of colonization and infection with Stenotrophomonas maltophilia in preterm infants associated with contaminated tap water Epidemiol. Infect. 120 1998 251-256
245. Murray P.R. Baron E.J. Pfaller M.A. Tenover F.C. Yolken R.H. Manual of clinical microbiology 7th ed. 1999 ASM Press Washington
246. Denton M. Kerr K.G. Molecular epidemiology of Stenotrophomonas maltophilia isolated from cystic fibrosis patients J. Clin. Microbiol. 40 2002 1884
247. Demko C.A. Stern R.C. Doershuk C.F. Stenotrophomonas maltophilia in cystic fibrosis: incidence and prevalence Pediatr. Pulmonol. 25 1998 304-308
248. Joseph P. Meeks C. Biddick R. Weiland J. Koch B. LiPuma J.J. Evidence of inter-patient spread of a virulent strain of Achromobacter xylosoxidans among CF patients Pediatr. Pulmonol. 308 Suppl. 25 2003 A360
249. Krzewinski J.W. Nguyen C.D. Foster J.M. Burns J.L. Use of random amplified polymorphic DNA PCR to examine epidemiology of Stenotrophomonas maltophilia and Achromobacter (Alcaligenes) xylosoxidans from patients with cystic fibrosis J. Clin. Microbiol. 39 2001 3597-3602
250. Schulze-Robbecke R. Feldmann C. Fischeder R. Janning B. Exner M. Wahl G. Dental units: an environmental study of sources of potentially pathogenic mycobacteria Tuber. Lung Dis. 76 1995 318-323
251. Wallace R.J.Jr. Brown B.A. Griffith D.E. Nosocomial outbreaks/pseudo-outbreaks caused by nontuberculous mycobacteria Annu. Rev. Microbiol. 52 1998 453-490
252. Bange F.C. Brown B.A. Smaczny C. Wallace R.J.Jr. Bottger E.C. Lack of transmission of Mycobacterium abscessus among patients with cystic fibrosis attending a single clinic Clin. Infect. Dis. 32 2001 1648-1650
253. Aitken M.L. Burke W. McDonald G. Wallis C. Ramsey B. Nolan C. Nontuberculous mycobacterial disease in adult cystic fibrosis patients Chest 103 1993 1096-1099
254. Hjelt K. Hojlyng N. Howitz P. Illum N. Munk E. Valerius N.H. et al. The role of mycobacteria other than tuberculosis (MOTT) in patients with cystic fibrosis Scand. J. Infect. Dis. 26 1994 569-576
255. Torrens J.K. Dawkins P. Conway S.P. Moya E. Non-tuberculous mycobacteria in cystic fibrosis Thorax 53 1998 182-185
256. Bargon J. Dauletbaev N. Kohler B. Wolf M. Posselt H.G. Wagner T.O. Prophylactic antibiotic therapy is associated with an increased prevalence of Aspergillus colonization in adult cystic fibrosis patients Respir. Med. 93 1999 835-838
257. Cimon B. Symoens F. Zouhair R. Chabasse D. Nolard N. Defontaine A. et al. Molecular epidemiology of airway colonisation by Aspergillus fumigatus in cystic fibrosis patients J. Med. Microbiol. 50 2001 367-374
258. Cimon B. Zouhair R. Symoens F. Carrere J. Chabasse D. Bouchara J.P. Aspergillus terreus in a cystic fibrosis clinic: environmental distribution and patient colonization pattern J. Hosp. Infect. 53 2003 81-82
259. Wenzel R.P. Prevention and control of nosocomial infection 1997 Williams and Wilkins Baltimore
260. Ogle J.W. Janda J.M. Woods D.E. Vasil M.L. Characterization and use of a DNA probe as an epidemiological marker for Pseudomonas aeruginosa J. Infect. Dis. 155 1987 119-126
261. Ojeniyi B. Petersen U.S. Høiby N. Comparison of genome fingerprinting with conventional typing methods used on Pseudomonas aeruginosa isolates from cystic fibrosis patients APMIS 101 1993 168-175
262. Hancock R.E. Mutharia L.M. Chan L. Darveau R.P. Speert D.P. Pier G.B. Pseudomonas aeruginosa isolates from patients with cystic fibrosis: a class of serum-sensitive, nontypable strains deficient in lipopolysaccharide O side chains Infect. Immun. 42 1983 170-177
263. Ojeniyi B. Frederiksen B. Høiby N. Pseudomonas aeruginosa cross-infection among patients with cystic fibrosis during a winter camp Pediatr. Pulmonol. 29 2000 177-181
264. Mahenthiralingam E. Campbell M.E. Foster J. Lam J.S. Speert D.P. Random amplified polymorphic DNA typing of Pseudomonas aeruginosa isolates recovered from patients with cystic fibrosis J. Clin. Microbiol. 34 1996 1129-1135
265. Tenover F.C. Arbeit R.D. Goering R.V. How to select and interpret molecular strain typing methods for epidemiological studies of bacterial infections: a review for healthcare epidemiologists. Molecular Typing Working Group of the Society for Healthcare Epidemiology of America Infect. Control Hosp. Epidemiol. 18 1997 426-439
266. Romling U. Tummler B. Achieving 100% typeability of Pseudomonas aeruginosa by pulsed-field gel electrophoresis J. Clin. Microbiol. 38 2000 464-465
267. Schlichting C. Branger C. Fournier J.-M. Witte W. Boutonnier A. Wolz C. et al. Typing of Staphylococcus aureus by pulsed field gel electrophoresis, zymotyping, capsular typing, and phage typing: resolution of clonal relationships J. Clin. Microbiol. 31 1993 227-232
268. Cheng K. Smyth R.L. Govan J.R. Doherty C. Winstanley C. Denning N. et al. Spread of beta-lactam-resistant Pseudomonas aeruginosa in a cystic fibrosis clinic Lancet 348 1996 639-642
269. Høiby N. Pedersen S.S. Estimated risk of cross-infection with Pseudomonas aeruginosa in Danish cystic fibrosis patients Acta Paediatr. Scand. 78 1989 395-404
270. Speert D.P. Lawton D. Damm S. Communicability of Pseudomonas aeruginosa in a cystic fibrosis summer camp J. Pediatr. 101 1982 227-228
271. Wolz C. Kiosz G. Ogle J.W. Vasil M.L. Botzenhart K. Döring G. Pseudomonas aeruginosa cross-colonization and persistence in patients with cystic fibrosis. Use of a DNA probe Epidemiol. Infect. 102 1989 205-214
272. Smith D.L. Smith E.G. Gumery L.B. Stableforth D.E. Dalla Costa L.M. Pitt T.L. Epidemiology of Pseudomonas aeruginosa infection in cystic fibrosis and the use of strain genotyping J. Infect. 26 1993 325-331
273. McCallum S.J. Corkill J. Gallagher M. Ledson M.J. Hart C.A. Walshaw M.J. et al. Superinfection with a transmissible strain of Pseudomonas aeruginosa in adults with cystic fibrosis chronically colonised by P. aeruginosa Lancet 358 2001 558-560
274. Jones A.M. Webb A.K. Govan J.R. Hart C.A. Walshaw M.J. Pseudomonas aeruginosa cross-infection in cystic fibrosis Lancet 359 2002 527-528
275. Zimakoff J. Kjelsberg A.B. Larsen S.O. Holstein B. A multicenter questionnaire investigation of attitudes toward hand hygiene, assessed by the staff in fifteen hospitals in Denmark and Norway Am. J. Infect. Control 20 1992 58-64
276. Fluge G. Ojeniyi B. Høiby N. Digranes A. Ciofu O. Hunstad E. et al. Typing of Pseudomonas aeruginosa strains in Norwegian cystic fibrosis patients Clin. Microbiol. Infect. 7 2001 238-243
277. Saiman L. Macdonald N. Burns J.L. Høiby N. Speert D.P. Weber D. Infection control in cystic fibrosis: practical recommendations for the hospital, clinic, and social settings Am. J. Infect. Control 28 2000 381-385
278. Millar-Jones L. Paull A. Saunders Z. Goodchild M.C. Transmission of Pseudomonas cepacia among cystic fibrosis patients Lancet 340 1992-491
279. Tablan O.C. Nosocomially acquired Pseudomonas cepacia infection in patients with cystic fibrosis Infect. Control Hosp. Epidemiol. 14 1993 124-126
280. Pegues D.A. Carson L.A. Tablan O.C. FitzSimmons S.C. Roman S.B. Miller J.M. et al. Acquisition of Pseudomonas cepacia at summer camps for patients with cystic fibrosis. Summer Camp Study Group J. Pediatr. 124 1994 694-702
281. Holmes A. Nolan R. Taylor R. Finley R. Riley M. Jiang R.Z. et al. An epidemic of Burkholderia cepacia transmitted between patients with and without cystic fibrosis J. Infect. Dis. 179 1999 1197-1205
282. Humphreys H. Peckham D. Patel P. Knox A. Airborne dissemination of Burkholderia (Pseudomonas) cepacia from adult patients with cystic fibrosis Thorax 49 1994 1157-1159
283. Burdge D.R. Nakielna E.M. Noble M.A. Case-control and vector studies of nosocomial acquisition of Pseudomonas cepacia in adult patients with cystic fibrosis Infect. Control Hosp. Epidemiol. 14 1993 127-130
284. Chen J.S. Witzmann K.A. Spilker T. Fink R.J. LiPuma J.J. Endemicity and inter-city spread of Burkholderia cepacia genomovar III in cystic fibrosis J. Pediatr. 139 2001 643-649
285. Govan J.R.W. Hughes J.H. Vandamme P. Burkholderia cepacia: medical, taxonomic and ecological issues J. Med. Microbiol. 45 1996 395-407
286. Pitt T.L. Kaufmann M.E. Patel P.S. Benge L.C. Gaskin S. Livermore D.M. Type characterization and antibiotic susceptibility of Burkholderia (Pseudomonas) cepacia isolates from patients with cystic fibrosis in the United Kingdom and Republic of Ireland J. Med. Microbiol. 44 1996 203-210
287. Jörgensen I.M. Johansen H.K. Frederiksen B. Pressler T. Hansen A. Vandamme P. et al. Epidemic spread of Pandoraea apista; a new pathogen causing sever lung disease in cystic fibrosis patients Pediatr. Pulmonol. 36 2003 439-446
288. Thomassen M.J. Demko C.A. Doershuk C.F. Stern R.C. Klinger J.D. Pseudomonas cepacia: decrease in colonization in patients with cystic fibrosis Am. Rev. Respir. Dis. 134 1986 669-671
289. Paul M.L. Pegler M.M. Benn R.A. Molecular epidemiology of Burkholderia cepacia in two Australian cystic fibrosis centres J. Hosp. Infect. 38 1998 19-26
290. Hoogkamp-Korstanje J.A. Meis J.F. Kissing J. van der Laag J. Melchers W.J. Risk of cross-colonization and infection by Pseudomonas aeruginosa in a holiday camp for cystic fibrosis patients J. Clin. Microbiol. 33 1995 572-575
291. Zembrzuska-Sadkowska E. Sneum M. Ojeniyi B. Heiden L. Høiby N. Epidemiology of Pseudomonas aeruginosa infection and the role of contamination of the environment in the Danish Cystic Fibrosis Centre J. Hosp. Infect. 29 1995 1-7
292. Boyce J.M. Antiseptic technology: access, affordability, and acceptance Emerg. Infect. Dis. 7 2001 231-233
293. The Burkholderia cepacia complex. Suggestions for Prevention and Infection Control. Report of the UK Cystic Fibrosis Trust Infection Control Group. Cystic Fibrosis Trust. Bromley, UK; 2004.
294. Perl T.M. Cullen J.J. Wenzel R.P. Zimmerman M.B. Pfaller M.A. Sheppard D. et al. Intranasal mupirocin to prevent postoperative Staphylococcus aureus infections. The-Mupirocin-And-The-Risk-Of-Staphylococcus-Aureus-Study-Team N. Engl. J. Med. 346 2002 1871-1877
295. Boe J. Dennis J.H. O'Driscoll B.R. Bauer T.T. Carone M. Dautzenberg B. et al. European Respiratory Society Task Force on the use of nebulizers. European Respiratory Society Guidelines on the use of nebulizers Eur. Respir. J. 18 2001 228-242
296. Bush A. Bisgaard H. Geddes D. Lannefors L. Nebulizers in cystic fibrosis Eur. Respir. Rev. 10 2000 552-557
297. International Physiotherapy Group for Cystic Fibrosis-Cystic Fibrosis Worldwide Physiotherapy in the treatment of cystic fibrosis (CF)3rd ed. 2002 http://www.cfww.org/pub/Physiotherapy.pdf
298. Jaffe A. Bush A. Cystic fibrosis: review of the decade Monaldi Arch. Chest Dis. 56 2001 240-247
299. Boucher R.C. An overview of the pathogenesis of cystic fibrosis lung disease Adv. Drug Deliv. Rev. 54 2002 1359-1371
300. Button B.M. Oberwaldner B. Carr M. Story I. The development of international guidelines for the physiotherapy managements of infants with CF: results of a worldwide survey forming the foundations of the project-A European Respiratory Society (ERS) task force project endorsed by the IPG/CF Pediatr. Pulmonol. Suppl. 22 2001 A399
301. van der Schans C. Prasad A. Main E. Chest physiotherapy compared to no chest physiotherapy for cystic fibrosis Cochrane Database Syst. Rev. 2 2000 CD001401
302. Bradley J. Moran F. Physical training for cystic fibrosis Cochrane Database Syst. Rev. 2 2002 CD002768
303. Desmond K.J. Schwenk W.F. Thomas E. Beaudry P.H. Coates A.L. Immediate and long-term effects of chest physiotherapy in patients with cystic fibrosis J. Pediatr. 103 1983 538-542
304. Bosworth D.G. Nielson D.W. Effectiveness of home versus hospital care in the routine treatment of cystic fibrosis Pediatr. Pulmonol. 24 1997 42-47
305. Accurso F.J. Early pulmonary disease in cystic fibrosis Curr. Opin. Pulm. Med. 3 1997 400-403
306. Button B.M. Physiotherapy in infants: time for a change J. Cyst. Fibros. 1 Suppl. 1 2002 S3:58
307. Munck A. Castaing M. Faure C. Viarme F. Gerardin M. Ajzenman C. et al. Acquisition of P. aeruginosa in CF children under 3 years: potential role of gastro-esophageal reflux (GER) J. Cyst. Fibros. 2001 P122
308. Demont B. Escourrou P. Vincon C. Cambas C.H. Grisan A. Odievre M. Effects of respiratory physical therapy and nasopharyngeal suction on gastroesophageal reflux in infants less than a year of age, with or without abnormal reflux Arch. Fr. Pediatr. 48 1991 621-625
309. Button B.M. Heine R.G. Catto-Smith A.G. Phelan P.D. Olinsky A. Postural drainage and GOR in infants with cystic fibrosis Arch. Dis. Child. 76 1997 148-150
310. Orenstein D.M. Heads up! Clear those airways Pediatr. Pulmonol. 35 2003 160-161
311. Phillips G.E. Pike S.E. Rosenthal M. Bush A. Holding the baby: head downwards positioning for physiotherapy does not cause gastro-oesophageal reflux Eur. Respir. J. 12 1998 954-957
312. Costantini D. Brivio A. Brusa D. Delfino R. Fredella C. Russo M. et al. PEP-Mask versus postural drainage in CF infants: a long-term comparative trial Pediatr. Pulmonol. Suppl. 22 2001 A400
313. van Ginderdeuren F. Malfroot A. Dab I. Influence of "assisted autogenic drainage (AAD)", bouncing and "AAD combined with bouncing" on gastroesophageal (GOR) reflux in infants J. Cyst. Fibros. 2001 P112
314. Elkin S.L. Fairney A. Burnett S. Kemp M. Kyd P. Burgess J. et al. Vertebral deformities and low bone mineral density in adults with cystic fibrosis: a cross-sectional study Osteoporos. Int. 12 2001 366-372
315. Nixon P.A. Orenstein D.M. Kelsey S.F. Habitual physical activity in children and adolescents with cystic fibrosis Med. Sci. Sports Exerc. 33 2001 30-35
316. Gross P.A. Barrett T.L. Dellinger E.P. Krause P.J. Martone W.J. McGowan J.E. et al. Purpose of quality standards for infectious diseases Clin. Infect. Dis. 18 1994 421
317. Warren J.W. Abrutyn E. Hebel J.R. Johnson J.R. Schaffer A.J. Stamm W.E. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women Clin. Infect. Dis. 29 1999 745-758